Semaglutide was first developed to battle Type-2 diabetes, but then, two years ago, the FDA cleared its use for treatment of chronic obesity, as it effectively curbs the appetites of many who take it
This makes it much easier to adopt and stick with healthier eating habits for good, because youre working with your bodys chemistry, not against it
118 It also causes small dose-dependent inhibition in food intake in both lean and overweight subjects
Clostridium butyricum was analyzed in a 2023 medical review, and the study authors stated it "reduced obesity" (in a rodent model)
They use active ingredients that may be sourced from FDA-registered facilities, but the finished compounded product itself has not gone through FDA review and approval
Insurance coverage varies widely, and many plans dont cover weight loss medications or require extensive prior authorization